These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2951089)

  • 1. The subcutaneous absorption of human and bovine ultralente insulin formulations.
    Hildebrandt P; Berger A; Vølund A; Kühl C
    Diabet Med; 1985 Sep; 2(5):355-9. PubMed ID: 2951089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human, porcine and bovine ultralente insulin: subcutaneous administration in normal man.
    Owens DR; Vora JP; Heding LG; Luzio S; Ryder RE; Atiea J; Hayes TM
    Diabet Med; 1986; 3(4):326-9. PubMed ID: 2949920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the safety and effectiveness of human and bovine long-acting insulins.
    Selam JL; Turner D; Woertz L; Eichner HL; Lauritano A; Charles MA
    Diabetes Res; 1989 Nov; 12(3):131-4. PubMed ID: 2635094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human ultralente insulin.
    Holman RR; Steemson J; Darling P; Reeves WG; Turner RC
    Br Med J (Clin Res Ed); 1984 Mar; 288(6418):665-8. PubMed ID: 6421424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of beef ultralente for basal insulin delivery: plasma insulin concentrations after chronic ultralente administration in patients with IDDM.
    Rizza RA; O'Brien PC; Service FJ
    Diabetes Care; 1986; 9(2):120-3. PubMed ID: 3698778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of human ultralente- and lente-based twice-daily injection regimens.
    Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
    Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue.
    Jørgensen S; Vaag A; Langkjaer L; Hougaard P; Markussen J
    BMJ; 1989 Aug; 299(6696):415-9. PubMed ID: 2506998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between subcutaneous blood flow and absorption of lente type insulin.
    Hildebrant P; Mehlsen J; Birch K; Kühl C
    Diabetes Res; 1987 Apr; 4(4):179-81. PubMed ID: 3621801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles.
    Lindström T; Olsson PO; Arnqvist HJ
    Scand J Clin Lab Invest; 2000 Aug; 60(5):341-7. PubMed ID: 11003253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics.
    Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Torjesen P; Try K
    Scand J Clin Lab Invest; 1989 Nov; 49(7):653-9. PubMed ID: 2692136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of human ultralente as the basal insulin component in treatment of patients with IDDM.
    Freeman SL; O'Brien PC; Rizza RA
    Diabetes Res Clin Pract; 1991 Jul; 12(3):187-92. PubMed ID: 1889348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent subcutaneous absorption of porcine, bovine and human NPH insulins.
    Hildebrandt P; Birch K; Sestoft L; Vølund A
    Acta Med Scand; 1984; 215(1):69-73. PubMed ID: 6364700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia.
    Francis AJ; Hanning I; Alberti KG
    Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of accidental intramuscular injection on insulin absorption in IDDM.
    Frid A; Gunnarsson R; Güntner P; Linde B
    Diabetes Care; 1988 Jan; 11(1):41-5. PubMed ID: 3276476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Miscibility of human and bovine ultralente insulin with soluble insulin.
    Mühlhauser I; Broermann C; Tsotsalas M; Berger M
    Br Med J (Clin Res Ed); 1984 Dec; 289(6459):1656-7. PubMed ID: 6439364
    [No Abstract]   [Full Text] [Related]  

  • 19. Human Monotard insulin: dose-dependent subcutaneous absorption.
    Hildebrandt P; Birch K; Sestoft L; Vølund A
    Diabetes Res; 1984 Nov; 1(4):183-5. PubMed ID: 6529890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of morning and bed-time ultralente administration when using multiple injections in adolescence.
    Smith CP; Dunger DB; Mitten S; Hewitt J; Spowart K; Grant DB; Savage MO
    Diabet Med; 1988; 5(4):352-5. PubMed ID: 2968885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.